Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Working Capital Changes (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Other Working Capital Changes data on record, last reported at -$1.3 million in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 146.78% year-over-year to -$1.3 million; the TTM value through Sep 2025 reached -$9.2 million, down 82.06%, while the annual FY2024 figure was -$5.6 million, 45.6% up from the prior year.
  • Other Working Capital Changes reached -$1.3 million in Q3 2025 per SGMO's latest filing, up from -$4.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $149.1 million in Q3 2023 and bottomed at -$149.8 million in Q1 2023.
  • Average Other Working Capital Changes over 5 years is -$959315.8, with a median of -$2.8 million recorded in 2024.
  • Peak YoY movement for Other Working Capital Changes: plummeted 613.04% in 2023, then surged 14516.67% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$5.3 million in 2021, then skyrocketed by 162.64% to $3.3 million in 2022, then tumbled by 254.97% to -$5.1 million in 2023, then decreased by 10.16% to -$5.6 million in 2024, then soared by 76.19% to -$1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$1.3 million in Q3 2025, -$4.9 million in Q2 2025, and $2.6 million in Q1 2025.